<DOC>
	<DOC>NCT02532309</DOC>
	<brief_summary>This is a 2-year, open-label, randomized study to evaluate the efficacy of Rosuvastatin dosing adjustment by LDL-C level compared to that of 5mg maintenance dose in chinese patients with Carotid Atherosclerosis.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques</brief_title>
	<detailed_description>This will be a 2-year, randomized, open-label, prospective, parallel-group study. It only be held in China-Japan Friendship Hospital. Subjects with Carotid Atherosclerosis Plaques who meet all inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to receive treatment of rosuvastatin (5 mg, 10mg, 20mg) dosing adjustment by LDL-c level or fixed dose 5 mg. The study will consist of two phases: the Screening/Baseline period（-1to week 0）and the Follow-up period(0 to month 24). The follow-up period will comprise seven visits.</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Plaque, Atherosclerotic</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Subjects or legal guardian can understand and sign the written informed consent form; LDLC≥100mg/dl（2.6mmol/l）. Subjects with carotid atherosclerotic noncalcified plaques determined by color Doppler ultrasound on carotid. ( Plaque defined as limited intima media thickness≥1.5mm, according to the procedure of vascular ultrasound examination in 2009 Chinese Journal of Ultrasonography ) Subjects had not been treated with statins, or one had been treated with antihyperlipidemics no more than 3 months within 12 months prior to screening. Subjects known to be allergic to the study medication, or any components . Uncontrolled hypothyroidism defined as the systolic blood pressure(SBP) &gt;180 mmHg or the diastolic blood pressure(DBP) ＞100 mmHg. Concomitant with severe or frequent arrhythmia, such as Atrial Fibrillation, second or third degree Atrioventricular Block, Sick sinus Syndrome etc. Alanine aminotransaminase (ALT) and /or Aspartate aminotransferase (AST) &gt;1.5×ULN (upper limit of normal). Subjects with myopathies，or the value of Creatine kinase &gt;1.5×ULN (upper limit of normal). Concomitant with chronic wasting diseases, whose life span was anticipated no longer than 2 years. Pregnant or nursing woman, and subjects with a Pregnant plan during this study. Cognitive impairment, which may affect obtaining informed consent and participating in the study procedures. Unwilling to receive treatment or examinations outlined in protocol.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Rosuvastatin</keyword>
	<keyword>Carotid Atherosclerosis plaque</keyword>
	<keyword>Crestor</keyword>
	<keyword>Rosuvastatin calcium</keyword>
</DOC>